Royal Bank of Canada Purchases 22,248 Shares of uniQure N.V. $QURE

Royal Bank of Canada lifted its position in uniQure N.V. (NASDAQ:QURE) by 26.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 107,888 shares of the biotechnology company’s stock after buying an additional 22,248 shares during the quarter. Royal Bank of Canada’s holdings in uniQure were worth $1,763,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Avoro Capital Advisors LLC raised its holdings in uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after acquiring an additional 1,705,556 shares during the period. State Street Corp boosted its holdings in uniQure by 123.8% during the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after acquiring an additional 1,787,033 shares during the period. JPMorgan Chase & Co. boosted its holdings in uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares during the period. Orbimed Advisors LLC grew its position in shares of uniQure by 189.7% in the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after purchasing an additional 1,398,749 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in shares of uniQure by 23.9% in the third quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock valued at $116,073,000 after purchasing an additional 383,066 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

QURE has been the subject of several research analyst reports. Mizuho boosted their price objective on uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Wells Fargo & Company raised their target price on uniQure from $60.00 to $75.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research report on Saturday. Wolfe Research upgraded uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target for the company in a report on Wednesday, July 29th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of uniQure in a research report on Friday, June 26th. Thirteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, uniQure presently has an average rating of “Moderate Buy” and a consensus price target of $65.00.

Insider Activity

In other uniQure news, insider Walid Abi-Saab sold 30,000 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $46.42, for a total value of $1,392,600.00. Following the transaction, the insider directly owned 148,235 shares in the company, valued at $6,881,068.70. The trade was a 16.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 21,167 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total transaction of $982,995.48. Following the sale, the director directly owned 25,996 shares in the company, valued at $1,207,254.24. This represents a 44.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 388,229 shares of company stock worth $16,817,099 in the last quarter. 4.65% of the stock is owned by company insiders.

uniQure Price Performance

Shares of QURE stock opened at $47.38 on Wednesday. The stock’s fifty day simple moving average is $42.10 and its 200 day simple moving average is $28.21. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50. The firm has a market cap of $3.29 billion, a price-to-earnings ratio of -11.82 and a beta of 0.93. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The company had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.During the same quarter in the prior year, the company earned ($0.69) earnings per share. On average, analysts expect that uniQure N.V. will post -3.74 earnings per share for the current fiscal year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.